Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation

Next Previous
Trial Profile

Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation

Suspended
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs PVX 410 (Primary) ; Influenza vaccine (Optaflu); Melphalan; Tetanus toxoid
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Feb 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 16 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 16 Feb 2018 Status changed from recruiting to suspended as protocol is being modified and moved to another institution
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top